The effectiveness and safety of RC48 alone or in combination with PD-1 inhibitors for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study

Table 2 ORR and mPFS of each treatment cohort

	mPFS	ORR
Neoadjuvant therapy RC48 alone RC48 combined with PD-1 inhibitors	/ / /	100.0% 100.0% 100.0%
First-line therapy RC48 alone RC48 combined with PD-1 inhibitors	6.1 5.0 6.2	47.4% 45.4% 50.0%
Second- or later-line therapy RC48 alone RC48 combined with PD-1 inhibitors	5.5 6.6 4.5	40.0% 33.3% 44.4%

ORR: The proportion of patients who achieved pre-specified tumor volume reduction and maintained the minimum time limit was the sum of complete and partial responses; PFS: The time between the start of randomization and the progression of tumor development (in any respect) or death (for any cause)

ISSN: 1479-5876